Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents

Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.

Adalimumab monoclonal antibody drug. Anti-inflammatory TNF-alpha inhibitor used in treatment of rheumatoid arthritis, psoriasis, ulcerative colitis, etc. Generic name and stylized antibody.

Pfizer Inc. joined the line of companies that have opted to license rights to AbbVie Inc.'s Humira (adalimumab) patents rather than challenge them in court.

Under a global agreement announced Nov. 30, Pfizer's license period in the US will begin on Nov. 20, 2023. That...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics